Respira closing $3M funding round; Noven nabs rights to Minivelle patch;

> Inhaled drug delivery company Respira Therapeutics is closing a $2 million to $3 million series B round, according to a report in MedCity News. The company will follow this up with a $15 million series C round to fund its pivotal clinical trials designed to support submission in Europe. Article

> Noven Pharmaceuticals has acquired the rights to the estradiol transdermal delivery system Minivelle from Novogyne Pharmaceuticals (a joint venture between Noven and Novartis) in the U.S. and Canada. Press release

> Biomarkers on the surface of cancer cells could funnel cancer drugs into malignant cells. Press release | Abstract

> Embedded mirrors made of gold and silk dissolve to release drugs. Article

> Genisphere is developing nanoparticles for cancer treatment and improving accuracy of tests. Article

> InSite Vision has completed enrollment of patients for the first Phase III clinical trial of BromSite, its delivery system to reduce pain and inflammation after cataract surgery. Article

> Santarus' once-daily, extended-release budesonide induces remission in patients with mild to moderate ulcerative colitis. Paper (pdf)

And Finally… A predatory fungus produces naturally occurring nanoparticles that could treat cancer. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.